Mark Schoenberg - 10 Jun 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
10 Jun 2024
Net transactions value
-$67,401
Form type
4
Filing time
11 Jun 2024, 13:15:23 UTC
Previous filing
20 Mar 2024
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +10,000 +7.2% 149,437 10 Jun 2024 Direct F1
transaction URGN Ordinary Shares Sale $67,401 -5,153 -3.4% $13.08 144,284 10 Jun 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -10,000 -33% $0.000000 20,000 10 Jun 2024 Ordinary Shares 10,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.